Tag: Mindset Pharma - Page 3 - Psychedelic Alpha

Read more about the article Mindset Pharma Appoints Dr. Fiona Randall as Senior Vice President of External Alliances and Scientific Strategy

Mindset Pharma Appoints Dr. Fiona Randall as Senior Vice President of External Alliances and Scientific Strategy

Post published:February 8, 2022
Post category:Press Release

Read more about the article Mindset Pharma Aims to Treat Broader Addressable Neurology Market by Studying Cognitive Benefits of its “Microdosing” Compounds

Mindset Pharma Aims to Treat Broader Addressable Neurology Market by Studying Cognitive Benefits of its “Microdosing” Compounds

Post published:February 3, 2022
Post category:Press Release

Read more about the article Mindset Pharma Enters Manufacturing Agreement with Leading CDMO to Produce Pharmaceutical Grade Batches of Next-Generation Psilocybin Drug Candidate, MSP-1014

Mindset Pharma Enters Manufacturing Agreement with Leading CDMO to Produce Pharmaceutical Grade Batches of Next-Generation Psilocybin Drug Candidate, MSP-1014

Post published:January 25, 2022
Post category:Press Release

Read more about the article The McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic Medicines

The McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic Medicines

Post published:January 5, 2022
Post category:Press Release

Read more about the article Mindset Pharma Announces Poster Presentation of Preclinical Data for Benchmarking Next-Generation Psychedelics at Neuroscience 2021

Mindset Pharma Announces Poster Presentation of Preclinical Data for Benchmarking Next-Generation Psychedelics at Neuroscience 2021

Post published:November 8, 2021
Post category:Press Release

Read more about the article Mindset Pharma Expands Benchmarking Data for First Generation Psychedelics Through the COPE Program with InterVivo Solutions

Mindset Pharma Expands Benchmarking Data for First Generation Psychedelics Through the COPE Program with InterVivo Solutions

Post published:October 14, 2021
Post category:Press Release

Read more about the article Mindset Pharma Expands Pipeline: Identifies Additional Next Generation 5-MeO-DMT-Inspired Lead Candidates

Mindset Pharma Expands Pipeline: Identifies Additional Next Generation 5-MeO-DMT-Inspired Lead Candidates

Post published:September 29, 2021
Post category:Press Release

Mindset Pharma Announces Further Preclinical Results Demonstrating Strong Efficacy and Improved Safety Profile for its 5-MeO-DMT-Inspired Drug Candidate, MSP-4018

Post published:September 20, 2021
Post category:Press Release

Read more about the article Mindset Pharma Further Validates Lead Candidate, MSP-1014, as a Next Generation Psilocybin Analog through Drug Discrimination Assay

Mindset Pharma Further Validates Lead Candidate, MSP-1014, as a Next Generation Psilocybin Analog through Drug Discrimination Assay

Post published:September 14, 2021
Post category:Press Release

Read more about the article Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its Novel Psilocybin-Inspired Clinical Candidate

Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its Novel Psilocybin-Inspired Clinical Candidate

Post published:September 9, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.